The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. MALMÖ, SE / ACCESS Newswire / January ...
(“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing ...
Natco Pharma Ltd on Thursday said it has received approval from the US health regulator for its generic version of Everolimus ...
Inc. stock despite strong Phase 2b data. Click for my updated look at MNMD stock and its market opportunities.
State Auditor Diana DiZoglio on Tuesday charged that Massachusetts is relying on a “broken system” for both executing and ...
Restrictive covenants could limit workers’ ability to report discrimination and harassment, two Lift Our Voices studies ...
The regulatory agency will review MSD’s new drug application (NDA) for Welireg under a Priority Review, with a Prescription ...
Highlights faulty FDA review WASHINGTON, Jan. 27, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provides an update on the tradipitant ...
Vanda Pharmaceuticals Inc. (Vanda) today provides an update on the tradipitant development program. Gastroparesis is a ...
( MENAFN - GlobeNewsWire - Nasdaq) NEW YORK, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Sage ...
The FDA rejected the company’s initial NDA in 2021, citing the lack of an adequate trial to demonstrate efficacy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback